AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01010698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimetidine (or acyclovir)
Description: cimetidine (or acyclovir) 200mg (single dose)
Study NCT01010698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cimetidine (or acyclovir)
Description: cimetidine (or acyclovir) 200mg (single dose)
Study NCT00263744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI 517
Description: Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
Study NCT00263744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
Study NCT04072289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visumax spherocylindrical treatment
Description: treatment of low cylinder (\<0.75D)
Study NCT01984372 — intervention group
Intervention type: DRUG
Intervention: insulin degludec
Description: Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
Study NCT03556436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH25448 240mg
Description: period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
Study NCT03331770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Ophthalmic Product
Description: Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
Study NCT01550250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night-time compression system garment
Description: Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
Study NCT01550250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Day-time compression sleeve
Description: Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
Study NCT01550250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day-time compression sleeve
Description: Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
Study NCT02058030 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insertion of ProSeal laryngeal mask airway
Description: The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed
Study NCT02058030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of ProSeal laryngeal mask airway
Description: The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed
Study NCT05417607 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: P-ESDM informed caregiver coaching
Description: Caregiver coaching informed by P-ESDM done remotely (via telehealth)
Study NCT02289170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating and cooling combination therapy
Description: The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
Study NCT02289170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham heating and cooling therapy
Description: The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
Study NCT02221453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Study NCT01750931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meloxicam GSK 15mg
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Study NCT01750931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mobic 15mg
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Study NCT04312035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: end-range mobilization
Description: accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
Study NCT04312035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non end-range mobilization
Description: accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
Study NCT04312035 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: hands-on cutaneous technique
Study NCT03827824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy & virtual reality glasses
Description: Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
Study NCT03827824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: Hysteroscopy. VAS. STAI scale.
Study NCT03827824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Hysteroscopy. VAS. STAI scale.
Study NCT00528580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80 mg once daily PO/NG x 4 days
Study NCT00528580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical-appearing placebo
Description: once daily x 4 days
Study NCT02741804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BBH-1001 Brain Health Supplement
Description: Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
Study NCT02741804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
Study NCT02741804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Intervention
Description: All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
Study NCT02741804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Placebo
Description: Treatment with placebo consisting of soybean oil
Study NCT00258011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 0.58 mg/kg every week
Study NCT02285777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ABCWY
Description: One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
Study NCT02285777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
Study NCT01515137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Study NCT01515137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus sulindac
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Study NCT01515137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Study NCT00807326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide/simeticone 2 mg/125 mg caplets
Description: Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
Study NCT00807326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide/simeticone 2 mg/125 mg chewable tablets
Description: Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
Study NCT00807326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Saccharomyces boulardii 250 mg capsules
Description: Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
Study NCT04643756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Classical electrotherapy method consisting of tens, hotpack and ultrasound.
Study NCT04643756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy plus kinesiotaping
Description: Conventional physiotherapy plus kinesiotaping
Study NCT01555047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: intrauterine insemination
Study NCT01555047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUI
Description: intrauterine insemination
Study NCT02597569 — intervention group
Intervention type: BEHAVIORAL
Intervention: CO-OP KT Exposure
Description: Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support.
Study NCT04006340 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: triple therapy
Description: esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
Study NCT04006340 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: triple therapy
Description: esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
Study NCT04006340 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: quadruple therapy
Description: esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
Study NCT04006340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual-priming oligonucleotide-based multiplex (DPO)-PCR test
Description: Resistance of clarithromycin 23S rRNA point mutation
Study NCT04046081 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dichloroacetate
Description: 6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
Study NCT00332254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 150 mg IL1Ra ia x1 vs saline ia x1
Study NCT00332254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra
Description: 150 mg IL1Ra ia x1 vs saline ia x1
Study NCT04204863 — intervention group
Intervention type: OTHER
Intervention: collection of patient data
Description: Extract data from the digital medical records, the electroencephalographic and microbiologic database.
Study NCT05679336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Cyclophosphamide, and Corticosteroids
Description: 1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count >5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7).
Study NCT03082105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in snow
Description: Breathing in snow with different physical properties
Study NCT00535275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy with platine
Description: Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Study NCT00535275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy without Cisplatine
Description: Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Study NCT04521829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking with different optic flow speeds with 2 different VR devices
Description: Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
Study NCT02964026 — intervention group
Intervention type: DEVICE
Intervention: pulmonary artery catheter
Description: PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
Study NCT04016831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mapping Enhanced Counseling (MEC)
Description: a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
Study NCT04016831 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mapping Enhanced Counseling (MEC)
Description: a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
Study NCT04016831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)
Description: an implementation intervention to explore and address agency preparation needs in order to promote implementation success
Study NCT02768233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational programme
Description: The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
Study NCT02398708 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Both groups will have questionnaires collected and compared.
Study NCT02398708 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: Both groups will have a blood sample collected and compared.
Study NCT02398708 — intervention group
Intervention type: OTHER
Intervention: Stool Sample
Description: Both groups will have a stool sample collected and compared.
Study NCT02398708 — intervention group
Intervention type: OTHER
Intervention: Clinical data
Description: Both groups will have clinical data collected and compared.
Study NCT04349982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)
Description: Factorial
Study NCT01421940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
Study NCT01421940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
Study NCT02390479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT02390479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT04607148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galegenimab
Description: Intravitreal (ITV) injections of galegenimab
Study NCT04206748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iGlucose Smart Meter System
Description: Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
Study NCT04206748 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care-RX meter
Description: Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
Study NCT00528515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan (propofol), Astra-Zeneca
Description: continuous intravenous infusion with a dose of 3-5 mg/kg/h
Study NCT00528515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suprane (desflurane), Baxter
Description: a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
Study NCT03135275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged complete PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
Study NCT03135275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate complete PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
Study NCT03135275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy™ stent
Description: Bioabsorbable Polymer Drug-Eluting Stent
Study NCT03135275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy™ stent
Description: Bioabsorbable Polymer Drug-Eluting Stent
Study NCT04350255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II hemispherical cup
Study NCT04350255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II Tritanium cup
Study NCT05231499 — intervention group
Intervention type: OTHER
Intervention: nasal irrigation
Description: regular saline nasal rinse
Study NCT04961268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TraMADol 50 Mg Oral Tablet
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study NCT04961268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 100 MG Oral Tablet
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study NCT04961268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600Mg Tab
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study NCT04961268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg/acetaminophen 1000 mg
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study NCT04961268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.